Abstract
AbstractOmalizumab, a humanized anti‐IgE monoclonal antibody, has been approved in Japan for the treatment of antihistamine‐resistant idiopathic chronic spontaneous urticaria. We herein report a 27‐year‐old Japanese woman suffering from a 2‐year history of severe cholinergic urticaria (sweat allergy‐type), which was unresponsive to various H2‐antihistamines and other medication but was successfully treated with omalizumab. The patient showed rapid and marked reduction in her symptoms of urticaria after the first injection of omalizumab (300 mg). She has been receiving omalizumab treatment quaque 4 weeks (q4w) three times and subsequent q6w six times, followed by maintenance treatment q8w without any adverse reactions for a total of 68 weeks. Although further large‐scale clinical investigation is needed, omalizumab may be a beneficial therapeutic remedy for patients with intractable, chronic inducible urticaria including cholinergic urticaria.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
